2cureX AB (publ) (STO:2CUREX)

Market Cap	13.40M -78.1%
Revenue (ttm)	1.98M -49.7%
Net Income	-26.35M
EPS	-1.50
Shares Out	31.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	380,699
Open	0.5000
Previous Close	0.4780
Day's Range	0.4100 - 0.5290
52-Week Range	0.4000 - 3.2700
Beta	2.93
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About 2cureX AB

2cureX AB (publ) operates as a medical technology company in Europe. ts proprietary IndiTreat test family creates various three-dimensional tumoroids derived from fresh samples of colorectal cancer (CRC) tissue that has been obtained from an individual patient’s metastatic colorectal cancer. 2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 14
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: 2CUREX

Financial Performance

In 2023, 2cureX AB's revenue was 2.95 million, a decrease of -12.53% compared to the previous year's 3.37 million. Losses were -32.52 million, 9.23% more than in 2022.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 1, 2026

Data Sources Report a data error